U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron’s Lomecel-B™ Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants
August 31, 2022 08:30 ET
|
Longeveron
MIAMI, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
Longeveron Receives Intent to Grant Notice from the European Patent Office for Methods to Monitor Efficacy of Lomecel-B™ Cell Therapy Through Levels of Vascular Biomarker
August 25, 2022 08:00 ET
|
Longeveron
MIAMI, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening...
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 12, 2022 08:00 ET
|
Longeveron
—Longeveron’s Phase 2a trial of Lomecel-B for patients with mild Alzheimer’s Disease proceeding on schedule, currently at 50% enrollment – Japanese Pharmaceuticals and Medical Devices...
Longeveron to Announce Second Quarter 2022 Financial Results on August 12, 2022
August 08, 2022 08:30 ET
|
Longeveron
MIAMI, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related...
Longeveron Announces Abstract Accepted for Presentation at the Alzheimer’s Association International Conference (AAIC)
July 07, 2022 08:00 ET
|
Longeveron
MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening...
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 13, 2022 08:00 ET
|
Longeveron
MIAMI, May 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and...
Longeveron Announces CEO Transition
May 09, 2022 16:15 ET
|
Longeveron
-Geoff Green stepping down as CEO, effective June 1, 2022 -K. Chris Min, M.D., Ph.D., current Chief Medical Officer, appointed Interim CEO -Nationwide search is underway for permanent CEO MIAMI,...
Longeveron to Announce First Quarter 2022 Financial Results on May 13, 2022
May 09, 2022 08:30 ET
|
Longeveron
MIAMI, May 09, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and...
Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference
April 14, 2022 08:58 ET
|
Longeveron
MIAMI, April 14, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
April 13, 2022 08:00 ET
|
Longeveron
MIAMI, April 13, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related...